Letter to the Editor

Free Access

Halahleh K.A.a· Ma’koseh M.a· Sultan I.b· Rimawi D.H.c· Muradi E.d· Gale R.P.e

Author affiliations

aDepartment of Internal Medicine-Hematology Oncology and Bone Marrow Transplantation, King Hussein Cancer Center, Amman, Jordan
bDepartment of Pediatrics, Hematology and medical Oncology, King Hussein Cancer Center, Amman, Jordan
cBiostatistics Unit, Research Office, King Hussein Cancer Center, Amman, Jordan
dDepartment of Internal Medicine, University of Tripoli, Tripoli, Libya
eDepartment of Immunology and Inflammation, Centre for Haematology Research, Imperial College London, London, UK

Corresponding Author

Khalid Abdelrahman Halahleh, abuannas@hotmail.com

First-Page Preview
References Ganapule A, Nemani S, Korula A, Lakshmi KM, Abraham A, Srivastava A, et al. Allogeneic stem cell transplant for acute myeloid leukemia: evolution of an effective strategy in India. J Glob Oncol 2017; 3(6):773–81. Giralt S. Busulfan based conditioning regimens: not all partners are equal. Lancet Oncol. 2015 16(15):1448–9. Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transpl. 2015; 50(Suppl 2):S37–9. Sora F, Grazia CD, Chiusolo P, Raiola AM, Bregante S, Mordini N, et al. Allogeneic hHemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with busulfan and fludarabine (BUFLU) or thiotepa, busulfan and fludarabine (TBF): a retrospective study. Biol Blood Marrow Transplant. 2020;26:698–703. Saraceni F, Beohou E, Labopin M, Arcese W, Bonifazi F, Stepensky P, et al. Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Am J Hematol. 2018;93(10):1211–9. Bacigalupo A, Maria Raiola A, Dominietto A, Di Grazia C, Gualandi F, Lint MTV, et al. Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients. Bone Marrow Transpl. 2019;54(Suppl 2):708–12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15(6):825–8. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working Group report. Biol Blood Marrow Transpl. 2015; 21(3):389–401.e1. Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753–67. Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow transplant Registry and the American society of blood and marrow transplantation. Biol Blood Marrow Transpl. 2001;7:473–85. Article / Publication Details

Received: June 02, 2022
Accepted: November 05, 2022
Published online: November 29, 2022

Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 1

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: https://www.karger.com/AHA

Figures Tables Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.